The use of locoregional therapies in cholangiocarcinoma.

This provides the benchmark against which additional locoregional therapies are evaluated.

这为评估额外的局部区域治疗提供了基准。

This narrative literature review examined locoregional therapies, their clinical outcomes, and recommendations for their role in the management of patients with CCA.

这篇叙述性文献综述检查了局部区域治疗、它们的临床结果以及它们在CCA患者管理中的作用建议。

The review focused on intrahepatic (iCCA) and perihilar CCA (pCCA) with locoregional disease in patients who were ineligible for surgical resection.

综述侧重于肝内（iCCA）和肝门部CCA（pCCA）患者，这些患者有局部区域疾病且不适合手术切除。

A literature search was conducted in PubMed (MEDLINE) to identify clinical studies evaluating locoregional therapies in CCA.

在PubMed（MEDLINE）中进行了文献搜索，以确定评估CCA中局部区域治疗的临床研究。

Ongoing and completed trials were identified through ClinicalTrials.gov.

通过ClinicalTrials.gov识别了正在进行和已完成的试验。

For iCCA, clinical trials have evaluated percutaneous image-guided local ablative therapies, including radiofrequency ablation or microwave ablation (3-year OS 42%), cryoablation, interstitial electroporation, and brachytherapy.

对于iCCA，临床试验已经评估了经皮影像引导的局部消融治疗，包括射频消融或微波消融（3年生存率为42%）、冷冻消融、间质电穿孔和近距离放射治疗。

Other trials have analysed external beam radiotherapy (EBRT), often using high-precision techniques (3-year OS 38%), as well as intra-arterial therapies, including transarterial chemoembolisation (3-year OS 17%), selective internal radioembolisation (3-year OS 40%), and floxuridine delivery through a hepatic arterial infusion pump (3-year OS 26-50%).

其他试验分析了外部束放射治疗（EBRT），通常使用高精度技术（3年生存率为38%），以及动脉内治疗，包括经动脉化疗栓塞（3年生存率为17%）、选择性内放射栓塞（3年生存率为40%），以及通过肝动脉输注泵输注的氟尿嘧啶（3年生存率为26-50%）。

For pCCA, EBRT has been evaluated in three treatment settings: definitive therapy (1-year OS 100%), adjuvant postoperative therapy (3-year OS 58%), and neoadjuvant therapy before liver transplantation (3-year OS 62%).

对于pCCA，体外放射治疗（EBRT）已在三种治疗环境中进行了评估：确定性治疗（1年生存率100%），术后辅助治疗（3年生存率58%），以及肝脏移植前的辅助治疗（3年生存率62%）。

Recent and ongoing clinical trials demonstrate a clear trend toward combining locoregional and standard-of-care systemic therapies.

最近和正在进行的临床试验明显显示出将局部区域治疗和标准的全身治疗相结合的趋势。

Few randomised controlled trials have been conducted.

很少进行随机对照试验。

Until further evidence from randomised controlled trials becomes available, treatment strategies for patients with unresectable or advanced CCA should be individualised, incorporating flexible, staged combinations of locoregional and systemic therapies within a personalised therapeutic framework.

在随机对照试验的进一步证据可用之前，对于无法切除或晚期CCA患者的治疗策略应个体化，应在个性化治疗框架内灵活地采用局部区域和全身治疗的分阶段组合。

These decisions should be made within a multidisciplinary tumour board.

这些决定应在多学科肿瘤委员会内作出。